Free Trial

Silence Therapeutics (SLN) Competitors

Silence Therapeutics logo
$5.30 +0.29 (+5.69%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SLN vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Silence Therapeutics vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Silence Therapeutics (NASDAQ:SLN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

180 Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -294.20%. 180 Life Sciences' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Silence Therapeutics -294.20%-67.48%-40.47%

Silence Therapeutics has a consensus price target of $32.60, indicating a potential upside of 512.21%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Silence Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

180 Life Sciences has higher earnings, but lower revenue than Silence Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Silence Therapeutics$27.17M5.87-$45.31M-$1.65-3.23

In the previous week, Silence Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company Overall Sentiment
180 Life Sciences Neutral
Silence Therapeutics Neutral

Summary

Silence Therapeutics beats 180 Life Sciences on 7 of the 10 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLN vs. The Competition

MetricSilence TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$160.22M$2.53B$5.75B$9.89B
Dividend YieldN/A48.51%6.66%4.49%
P/E Ratio-3.2422.4682.9726.58
Price / Sales5.87533.51500.68162.32
Price / CashN/A26.3325.7028.92
Price / Book1.196.8010.796.52
Net Income-$45.31M$32.94M$3.29B$266.21M
7 Day Performance4.41%0.37%-0.07%-0.96%
1 Month Performance-10.50%6.42%6.98%3.61%
1 Year Performance-72.34%-0.70%49.86%24.03%

Silence Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLN
Silence Therapeutics
2.2508 of 5 stars
$5.30
+5.8%
$32.60
+515.1%
-73.9%$158.63M$27.17M-3.21100Gap Up
ATNFW
180 Life Sciences
N/A$0.22
+10.1%
N/A+1,961.9%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.40
-12.9%
N/AN/A$0.00$110.87K0.0040Positive News
Gap Up
ALVOW
Alvotech
N/A$1.17
-0.9%
N/A-56.1%$0.00$560.10M0.004Positive News
Gap Down
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
+6.5%
N/A-6.5%$0.00N/A0.0015Gap Down
BFRIW
Biofrontera
N/A$0.10
-0.1%
N/A+201.8%$0.00$39.19M0.0070Positive News
BTMDW
biote
N/A$0.01
-10.6%
N/A-96.2%$0.00$199.07M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.02
-14.8%
N/A-88.0%$0.00N/A0.008News Coverage
Short Interest ↓
Gap Down

Related Companies and Tools


This page (NASDAQ:SLN) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners